TY - JOUR
T1 - COVID-19 vaccination in patients with heart failure
T2 - a position paper of the Heart Failure Association of the European Society of Cardiology
AU - Rosano, Giuseppe
AU - Jankowska, Ewa A.
AU - Ray, Robin
AU - Metra, Marco
AU - Abdelhamid, Magdy
AU - Adamopoulos, Stamatis
AU - Anker, Stefan D.
AU - Bayes-Genis, Antoni
AU - Belenkov, Yury
AU - Gal, Tuvia B.
AU - Böhm, Michael
AU - Chioncel, Ovidiu
AU - Cohen-Solal, Alain
AU - Farmakis, Dimitrios
AU - Filippatos, Gerasimos
AU - González, Arantxa
AU - Gustafsson, Finn
AU - Hill, Loreena
AU - Jaarsma, Tiny
AU - Jouhra, Fadi
AU - Lainscak, Mitja
AU - Lambrinou, Ekaterini
AU - Lopatin, Yury
AU - Lund, Lars H.
AU - Milicic, Davor
AU - Moura, Brenda
AU - Mullens, Wilfried
AU - Piepoli, Massimo F.
AU - Ponikowski, Piotr
AU - Rakisheva, Amina
AU - Ristic, Arsen
AU - Savarese, Gianluigi
AU - Seferovic, Petar
AU - Senni, Michele
AU - Thum, Thomas
AU - Tocchetti, Carlo G.
AU - Van Linthout, Sophie
AU - Volterrani, Maurizio
AU - Coats, Andrew J.S.
N1 - Publisher Copyright:
© 2021 European Society of Cardiology
PY - 2021/11
Y1 - 2021/11
N2 - Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery, safety and efficacy of COVID-19 vaccines for patients with HF. This document provides guidance to all healthcare professionals regarding the implementation of a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination is indicated in all patients with HF, including those who are immunocompromised (e.g. after heart transplantation receiving immunosuppressive therapy) and with frailty syndrome. It is preferable to vaccinate against COVID-19 patients with HF in an optimal clinical state, which would include clinical stability, adequate hydration and nutrition, optimized treatment of HF and other comorbidities (including iron deficiency), but corrective measures should not be allowed to delay vaccination. Patients with HF who have been vaccinated against COVID-19 need to continue precautionary measures, including the use of facemasks, hand hygiene and social distancing. Knowledge on strategies preventing SARS-CoV-2 infection (including the COVID-19 vaccination) should be included in the comprehensive educational programmes delivered to patients with HF.
AB - Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery, safety and efficacy of COVID-19 vaccines for patients with HF. This document provides guidance to all healthcare professionals regarding the implementation of a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination is indicated in all patients with HF, including those who are immunocompromised (e.g. after heart transplantation receiving immunosuppressive therapy) and with frailty syndrome. It is preferable to vaccinate against COVID-19 patients with HF in an optimal clinical state, which would include clinical stability, adequate hydration and nutrition, optimized treatment of HF and other comorbidities (including iron deficiency), but corrective measures should not be allowed to delay vaccination. Patients with HF who have been vaccinated against COVID-19 need to continue precautionary measures, including the use of facemasks, hand hygiene and social distancing. Knowledge on strategies preventing SARS-CoV-2 infection (including the COVID-19 vaccination) should be included in the comprehensive educational programmes delivered to patients with HF.
KW - COVID-19
KW - Heart failure
KW - SARS-CoV-2
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85118500592&partnerID=8YFLogxK
U2 - 10.1002/ejhf.2356
DO - 10.1002/ejhf.2356
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34612556
AN - SCOPUS:85118500592
SN - 1388-9842
VL - 23
SP - 1806
EP - 1818
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 11
ER -
